For investors, the focus of pumping in liquid cash into a stock is to have a consistent flow of income, and high yielding stocks deliver that. It’s for this reason that AbbVie Inc. (NYSE:ABBV), a biopharmaceutical company with a market capitalization of $93.11 billion, is famous among investors. With a dividend yield of 6.74% and a 4-year average of 3.94%, it’s clear that the stock boasts of a good yield. In fact, AbbVie Inc.’s dividend yield beats that of the S&P 500 by 4.80% and also beats the largest cap pharmaceuticals by 3.70%.
Considering dividend growth, the company’s current dividend growth of $4.28 represents a 19.2% increase over last year. For the past five years, the company’s dividend has significantly grown on year-over-year basis, with an annual average uptick of 20.20%. The company currently has a payout ratio of 52%. Having posted an increase over the last couple of years, more so because of its stability in the market, the stock is a good attraction for investors.
AbbVie Inc. (NYSE:ABBV) Earnings Reports
During this year, AbbVie Inc. (NYSE:ABBV) has faced some negative effects on its share price, but its quarterly results have shown that it’s fairing on well. In their latest quarterly earnings, the company beat Wall Street estimates. Even though the stock posted lower revenue and profit, the posting was better than analysts’ consensus estimates. The profit went down to 49 cents per share from $1.26 per share compared to the same quarter last year. The stock posted earnings per share of $2.26, which was above the $2.21 that was expected by analysts interviewed by FactSet.
No investor wants to put in their money on a stock that has no future. So, is it a good idea to pump in money in AbbView Inc.? Well, there are many reasons to invest in this stock. The fact that it currently has a dividend yield of 6.74% and it has a good looking future makes it a good choice for investors.
AbbView Inc. Company Profile
AbbView Inc. is a biopharmaceutical company based in Illinois, United States. AbbVie Inc. (NYSE:ABBV) has a market capitalization of $95.14 billion. Some of its subsidiaries are Stemcentrx, Inc., Mavupharama Inc., and Parmacyclics, among others.